

# Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer

A Randomized Clinical Trial

Chaft JE, Sun Z, Rudin CM, et al. *JAMA*. 2026:e268992. doi: 10.1001/jama.2026.8992




ANNENBERG CENTER FOR HEALTH SCIENCES

AT EISENHOWER

*Imparting knowledge. Improving patient care.*

# Adjuvant Nivolumab Efficacy (Overall Intent-to-Treat Population)



# Adjuvant Nivolumab Efficacy (PD-L1 $\geq$ 50% Population)

